Lethal effect of bleomycin and peplomycin on HeLa cells in multicell tumor spheroids. 1984

T Sasaki, and M Yamamoto, and K Kuwahara

The lethal effects of bleomycin and its derivative, peplomycin, were determined for HeLa S3 cells grown in multicell spheroids cocultured with human diploid fibroblasts. Both drugs were less effective for cells in spheroids than for cells grown exponentially in monolayers. However, HeLa cells from spheroids exposed to the drugs in single-cell suspension were more sensitive to the drugs than were cells in monolayers. Sequential trypsinization of spheroids after exposure to both drugs showed that the surviving fraction increased sharply with increasing depth of cell layers in the spheroids. The presence of 0.5 mM misonidazole, a hypoxic radiosensitizer, enhanced the lethal effect of peplomycin only for the cells in the deeper layer. These findings suggest that the drug resistance of cells in spheroids was due, at least in part, to the microenvironment of the deeper layers. When spheroids were incubated in fresh medium following exposure to both drugs, the cells recovered from the potentially lethal damage within 1 hr. The extent of the recovery from a fixed drug concentration was higher in cells of the superficial layers than in cells of the deeper layers. It is suggested that the limitation of the lethal effects of bleomycin and peplomycin in solid tumors may be overcome by improving the state of oxygenation of hypoxic cells and by combining either drug with one which inhibits recovery from potentially lethal damage.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008920 Misonidazole A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic. Ro 07-0582,Ro 7-0582,alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol,Ro 07 0582,Ro 070582,Ro 7 0582,Ro 70582
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D017663 Peplomycin An antineoplastic agent derived from BLEOMYCIN. Pepleomycin,NK-631,Peplomycin Sulfate,Peplomycin Sulfate (1:1),NK 631,NK631,Sulfate, Peplomycin

Related Publications

T Sasaki, and M Yamamoto, and K Kuwahara
March 2001, Bulletin of mathematical biology,
T Sasaki, and M Yamamoto, and K Kuwahara
June 2006, Lasers in surgery and medicine,
T Sasaki, and M Yamamoto, and K Kuwahara
May 1983, The Journal of antibiotics,
T Sasaki, and M Yamamoto, and K Kuwahara
November 1980, Cancer research,
T Sasaki, and M Yamamoto, and K Kuwahara
January 1986, Journal of cancer research and clinical oncology,
T Sasaki, and M Yamamoto, and K Kuwahara
June 1978, The British journal of cancer. Supplement,
T Sasaki, and M Yamamoto, and K Kuwahara
January 1986, Anticancer research,
T Sasaki, and M Yamamoto, and K Kuwahara
June 1977, The British journal of radiology,
T Sasaki, and M Yamamoto, and K Kuwahara
June 1970, The Journal of antibiotics,
Copied contents to your clipboard!